If you are fortunate enough to have $5,000 spare to invest into ASX 200 shares, then read on.
That's because listed below are three shares that analysts are tipping as top buys for the year ahead.
Here's what you need to know about them:
Analysts at Goldman Sachs are feeling positive about this beaten down pizza chain operator and see it as an ASX 200 share to buy.
After a difficult period, the broker believes that Domino's fortunes could be about to change for the better. This is thanks to its renewed focus on store unit economics. Goldman explains:
We believe that DMP's renewed focus on store unit economics and re-investment to ignite topline growth is rightly placed. While there is still significant progress to be made, we believe that earnings has troughed in FY24 and see a path of improvement through FY25.
The broker has a buy rating and $39.10 price target on its shares. This suggests that upside of 32% is possible from current levels.
Another ASX 200 share that could be a good option for a $5,000 investment is Neuren Pharmaceuticals.
It is a pharmaceuticals company developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options.
Analysts at Bell Potter are bullish on the company. It sees a lot of potential in the NNZ-2591 asset. It said:
Neuren Pharmaceuticals is a biotech company that is well-funded via its first asset, DAYBUE, which is an FDA approved trofinetide for the treatment of Rett syndrome. NEU's value is from its second asset, NNZ-2591, which is under development for rare diseases. NNZ-2591, if successful, could lead to a significant increase in revenue and earnings when brought to market. NEU looks attractive on a risk/adjusted basis after the recent sell-off.
Bell Potter has a buy rating and $25.00 price target on its shares. This implies potential upside of almost 90% for investors.
A third option for that $5,000 could be Treasury Wine shares. Goldman Sachs is also positive on the wine giant and sees it as an ASX 200 share to buy right now.
The broker believes its shares are undervalued based on its expectation that the company is destined to deliver double-digit earnings growth through to at least 2027. It explains:
Our Buy rating on TWE is premised on accelerating double-digit EPS growth in FY24-27e driven by 1) continued global expansion of Penfolds, especially post the removal of China import tariffs on Australian wine; our recent channel checks suggest positive reception to the returning Australian sourced Penfolds and we expect a ~63pct pre-tariff recovery by 2027.
The broker has a buy rating and $15.20 price target on its shares. This implies potential upside of 31% for investors from current levels.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.